Thirona has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest update of its AI-based clinical software LungQ™ (v3.0.0)
Thirona is thrilled to have secured €7,5 Million ($8 Million) of financing from HERAN Partners, Borski Fund and the EIC.
Thirona’s AI-Based LungQ™AVX Reveals New Potential for Treatment of Vascular Diseases.
Following the growing market demand and recent expansion of RetCAD™, Thirona decided spins it out as per January 1st,
Thirona is awarded ISO 27001 and NEN 7510 certifications.
Thirona and Free Flow Medical signed a partnership agreement to provide clinicians with advanced high-precision tools for treatment planning.